MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.
暂无分享,去创建一个
H. Wakelee | E. Smit | T. Mok | Yi-long Wu | S. Novello | F. de Marinis | L. Paz-Ares | J. Yang | T. Seto | V. Hirsh | Li Zhang | O. Aren | C. Peña | E. Juhász | Yan Sun | T. Schmelter | T. Ong